Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics Q2 revenue falls to $178.9 million; net loss narrows to $64.8 million

Mixed Impact 3 of 5 earnings Written later

PTC Therapeutics reported second-quarter 2025 total revenue of $178.9 million, down from $186.7 million a year earlier, while its net loss narrowed to $64.8 million from $99.2 million. The company also reaffirmed no prior guidance in this filing but gave full-year 2025 revenue guidance of $650 million to $800 million, and said Sephience received FDA approval on July 28, 2025.

Key points

  • Q2 2025 total revenue $178.9 million vs. $186.7 million in Q2 2024; net product revenue $118.3 million vs. $133.2 million
  • Q2 2025 net loss $64.8 million, or $0.83 per share, vs. net loss of $99.2 million, or $1.29 per share, in Q2 2024
  • Full-year 2025 revenue guidance of $650 million to $800 million
  • Agreed to buy the Sephience sales obligation owed to former Censa shareholders for a $225 million upfront payment; cash and marketable securities were $1,989.2 million at June 30, 2025

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECAug 7, 2025, 4:17 PM ET
Accession number0001558370-25-010770

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.